Figure S2 HIV protease inhibitors increase CD36 expression on cultured macrophages RAW264.7 cells. Ritonavir and atazanavir, two HIV PIs increases the cell surface expression of CD36 in a concentration-dependent manner. Data are mean 6 SE of 4 separate experiments. Natural and synthetic FXR ligands, CDCA and GW4064, counteracts CD36 induction caused by ritonavir and atazanavir. Data are mean6 SE of 4 separate experiments. Found at: doi:10.1371/journal.pone.0013238.s003 (0.18 MB TIF) Figure S3 Nubiscan analysis (http://www.nubiscan.unibas.ch) of the mouse CD36 promoter region revealed one potential SREBP1 binding site, TTCACACCAG, located at 21562 bp from the transcriptional starting site ATG. To assess the functionality of this SRE (Sterol Regulatory Element) we carried References 1. Flexner C (1998) HIV-protease inhibitors. N Engl J Med 338: 1281–1292. 2. Yeni P (2006) Update on HAART in HIV. Journal of Hepatology 44: S100–S103. 3. Mooser V (2003) Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS 17: S65–S69. 4. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, et al. (2003) Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 33(4): 506–12. 5. Carr A, Samaras K, Chisholm DJ, Cooper DA (1998) Pathogenesis of HIV-1- protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881–3. 6. Graham NM (2000) Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr 25: S4–S11. 7. Distler O, Cooper DA, Deckelbaum RJ, Sturley SL (2001) Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 4: 99–103. 8. Barbaro G (2005) Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc Haematol Disord 5: 337–43. 9. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY (2001) HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 276: 37514–37519. 10. Parker RA, Flint OP, Mulvey R, Elosua C, Wang F, et al. (2005) Endoplasmic reticulum stress links dyslipidemia to inhibition of proteasome activity and glucose transport by HIV protease inhibitors. Mol Pharmacol 67: 1909–1919. 11. Zhou H, Pandak WM, Jr., Lyall V, Natarajan R, Hylemon PB (2005) HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 68: 690–700. 12. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, et al. (2003) HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest 111: 389–97. 13. Silverstein RL, Febbraio M (2000) CD36 and atherosclerosis. Curr Opin Lipidol 11: 483–491. 14. Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, et al. (1999) Identification of a nuclear receptor for bile acids. Science 284: 1362–1365. 15. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, et al. (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102: 731–744. 16. Hartman HB, Gardell SJ, Petucci CJ, Wang S, Krueger JA, et al. (2009) Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR2/2 and apoE2/2 mice. J Lipid Res 50: 1090–100. 17. Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 296: H272–281. 18. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, et al. (2004) Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 113: 1408–1418. 19. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, et al. (2006) Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A 103: 1006–1011. 20. Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 51: 771–84. 21. Bateson MC, Maclean D, Evans JR, Bouchier IA (1978) Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. Br J Clin Pharmacol 5: 249–254. 22. Miller NE, Nestel PJ (1974) Triglyceride-lowering effect of chenodeoxycholic acid in patients with endogenous hypertriglyceridaemia. Lancet 2: 929–931. 23. Shimano H (2001) Sterol regulatory element binding proteins transcriptional regulators of lipid synthetic genes. Progress Lipid Res 40: 439–452. 24. Sato O, Kuriki C, Fukui Y, Motojima K (2002) Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional FXR and Anti-HIV Therapy a ChIP experiment with an anti SREBP1 antibody (see Materials and Methods S1). As shown, quantitative Real-Time PCR analysis of the CD36 5’flanking region revealed that SREBP1 was unable to bind to the promoter region containing the putative SRE in cells untreated as well as in cells stimulated with ritonavir alone or with the combination ritonavir plus CDCA. These results suggest that SREBP1 regulates CD36 expression with an indirect mechanism. Found at: doi:10.1371/journal.pone.0013238.s004 (0.61 MB TIF) Author Contributions Conceived and designed the experiments: DF ED FB SF. Performed the experiments: AM SC BR GP. Analyzed the data: AM SC SF. Wrote the paper: AM SC ED FB SF. activation by peroxisome proliferator-activated receptor alpha and gamma ligands. J Biol Chem 277: 15703–11. 25. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR- gamma. Cell 93: 229–240. 26. Fiorucci S, Cipriani S, Baldelli F, Mencarelli A (2010) Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 49: 171–85. 27. Hanniman EA, Lambert G, McCarthy TC, Sinal CJ (2005) Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E- deficient mice. J Lipid Res 46: 2595–2604. 28. Stein JH (2007) Cardiovascular Risks of Antiretroviral Therapy. N Engl J Med 356: 1773–5. 29. DAD Study Group (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356: 1723–35. 30. Lenhard JM, Croom DK, Weiel JE, Winegar DA (2000) HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 20: 2625–9. 31. Wang L, Lee YK, Bundman D, Han Y, Thevananther S, et al. (2002) Redundant pathways for negative feedback regulation of bile acid production. Dev Cell 2: 721–731. 32. Huang J, Iqbal J, Saha PK, Liu J, Chan L, et al. (2007) Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 46: 147–57. 33. Boulias K, Katrakili N, Bamberg K, Underhill P, Greenfield A, et al. (2005) Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO J 24: 2624–2633. 34. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, et al. (2002) Innate and acquired immunity in atherogenesis. Nat Med 8: 1218–1226. 35. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874. 36. Bishop-Bailey D, Walsh DT, Warner TD (2004) Expression and activation of the farnesoid X receptor in the vasculature. Proc Natl Acad Sci U S A 101: 3668–73. 37. Li YT, Swales KE, Thomas GJ, et al. (2007) Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler Thromb Vasc Biol 27: 2606–11. 38. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, et al. (1999) Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kB and AP-1. J Bio Chem 274: 32048–32054. 39. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, et al. (2007) Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17–2. 40. Calkin AC, Cooper ME, Jandeleit-Dahm KA, Allen TJ (2006) Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation. Diabetologia 49: 766–74. 41. Calkin AC, Allen TJ, Lassila M, Tikellis C, Jandeleit-Dahm KA, et al. (2007) Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse. Atherosclerosis 195: 17–22. 42. Linton MF, Fazio S (2001) Class A scavenger receptors, macrophages, and Atherosclerosis. Curr Opin Lipidol 12: 489–495. 43. Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, et al. (2001) Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci 947: 214–222. 44. Lee JY, Parks JS (2005) ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 16: 19–25. 45. Zhou J, Zhai Y, Mu Y, Gong H, Uppal H, Toma D, et al. (2006) A novel pregnane X receptor-mediated and sterol regulatory element-binding protein- independent lipogenic pathway. J Biol Chem 28: 15013–15020. 46. Jung D, Mangelsdorf DJ, Meyer UA (2006) Pregnane X receptor is a target of farnesoid X receptor. J Biol Chem 28: 19081–19091. PLoS ONE | www.plosone.org 13 October 2010 | Volume 5 | Issue 10 | e13238